Endo Pharmaceuticals Holdings Inc (ENDP) 42.44 $ENDP
Dow 30 Stock Roundup: Boeing Wins $276.3M Navy Contract, Cisco to Buy Cloud Startup for $260M
Swarup Gupta - Zacks Investment Research - Fri Mar 04, 2:52PM CST
The Dow continued to gain this week on the back of rising oil prices.
MMM: 160.07 (+0.69), ENDP: 42.44 (-0.73), GE: 30.46 (+0.24), XOM: 82.29 (-0.11), BA: 121.07 (+1.46), JNJ: 106.50 (-0.15), V: 73.90 (-0.01), ADP: 86.19 (+0.54), GS: 156.84 (+1.51), JPM: 60.05 (+0.09), PG: 83.49 (+0.65), CVX: 87.93 (+0.40), MSFT: 52.03 (-0.32), VZ: 51.81 (-0.08), AAPL: 103.01 (+1.51), CSCO: 26.80 (-0.07), BHI: 46.20 (-0.35)
Endo Int’l (ENDP) Stock Price Target Cut at Barclays
at The Street - Fri Mar 04, 8:51AM CST
Barclays lowered its price target on Endo Int’l (ENDP) stock and maintained its ‘equal weight’ rating on Friday morning.
ENDP: 42.44 (-0.73)
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2015 Update
John Vincent - at Seeking Alpha - Sun Feb 21, 6:17AM CST
SIRO: 109.97 (-0.13), MON: 85.89 (+0.95), EVHC: 23.25 (-0.30), PRU: 71.47 (-0.40), NKE: 61.26 (-0.21), KSU: 86.65 (+0.23), AMP: 90.46 (+0.92), LM: 32.42 (+0.57), RRC: 32.32 (+1.59), AET: 108.06 (-1.58), GOOG: 710.89 (-1.53), GPOR: 25.60 (+0.33), HOT: 70.55 (+0.48), HLT: 21.89 (+0.30), LYB: 82.00 (+2.10), COG: 21.47 (-0.70), WCG: 93.24 (-0.36), MA: 90.05 (+0.31), MNK: 62.15 (-1.44), WUBA: 55.70 (+1.45), WLL: 7.09 (+0.78), VRTX: 88.36 (-1.09), MCK: 162.77 (+0.07), ETN: 57.95 (+0.12), SEE: 45.68 (-0.84), AKRX: 25.08 (-0.80), PFE: 29.71 (-0.18), HAL: 34.88 (+0.71), LNG: 38.04 (+0.99), ETE: 8.33 (+0.43), TXT: 33.00 (-0.64), ALL: 65.38 (+0.07), PCLN: 1,297.71 (-5.33), QUNR: 36.95 (+0.73), WBA: 79.45 (-0.47), PXD: 128.80 (+0.53), MCD: 117.18 (+0.49), TEVA: 55.62 (+0.02), DOV: 63.20 (+0.75), AIG: 52.30 (+0.03), XRAY: 60.16 (-0.46), FDC: 13.59 (+0.80), CCI: 87.25 (-0.64), BIIB: 263.94 (-4.70), VRX: 61.31 (-3.58), CPN: 14.14 (+0.26), C: 42.83 (unch), ILMN: 156.14 (-1.31), CB: 117.18 (-0.66), MMC: 58.01 (+0.26), HUM: 183.25 (+0.03), AGN: 288.67 (-0.95), ANTM: 132.35 (-0.62), ECA: 5.47 (+0.54), PRQR: 4.54 (+0.14), EBAY: 24.41 (+0.47), SHPG: 160.39 (+0.20), CMG: 529.00 (+4.71), GOOGL: 730.22 (-1.37), CTRP: 40.02 (+0.78), SWN: 7.83 (+0.49), BK: 38.09 (+0.40), APD: 134.79 (-0.09), BHI: 46.20 (-0.35), APC: 45.26 (+2.28), AMZN: 575.14 (-2.35), ENDP: 42.44 (-0.73), MAR: 68.98 (+0.30), NFLX: 101.58 (+3.65), DVA: 70.51 (+0.43), KITE: 54.44 (+2.70), MHK: 186.82 (-0.07), TDG: 222.68 (+3.05), LH: 112.17 (+0.25), CP: 125.26 (+3.28), AFL: 61.03 (+0.05), AVGO: 146.06 (+8.73), BABA: 72.22 (+1.20)
Tracking John Paulson's Paulson & Company Portfolio - Q4 2015 Update
John Vincent - at Seeking Alpha - Sat Feb 20, 1:39PM CST
SGYP: 3.47 (-0.01), PRGO: 126.61 (+0.19), CAM: 67.79 (-0.03), CHTR: 184.78 (+1.11), INTC: 30.63 (+0.05), PCP: 234.95 (+0.10), SLB: 74.83 (-0.02), CYBX: 69.95 (+0.86), HOT: 70.55 (+0.48), STAY: 14.82 (-0.27), CSC: 30.51 (-0.26), TMUS: 38.48 (-0.49), MNK: 62.15 (-1.44), WLL: 7.09 (+0.78), AKRX: 25.08 (-0.80), NCQ: 0.46 (+0.05), AU: 12.92 (-0.36), MYL: 44.78 (-0.95), MGM: 19.81 (-0.52), WWAV: 41.15 (+0.60), NG: 5.02 (-0.01), LIVN: 57.94 (+0.19), TEVA: 55.62 (+0.02), AIG: 52.30 (+0.03), BRK.B: 137.97 (+1.13), BRK.A: 207,945.00 (+1,945.00), OAS: 6.91 (+0.22), VRX: 61.31 (-3.58), VNDA: 7.92 (-0.21), ALTR: 53.96 (+0.03), CZR: 8.80 (-0.15), CVC: 33.28 (+0.03), CIE: 3.41 (+0.21), AGN: 288.67 (-0.95), CACQ: 5.75 (-0.15), SHPG: 160.39 (+0.20), TWC: 195.33 (+0.90), BXLT: 39.47 (+0.17), ENDP: 42.44 (-0.73), OUT: 21.56 (+0.06), BAC: 13.54 (+0.04), MAR: 68.98 (+0.30), GRFS: 15.22 (-0.27), HCA: 73.00 (+0.07), POST: 71.75 (-0.45), RDN: 11.94 (+0.16), LRCX: 74.33 (-0.54), BAX: 39.46 (+0.13), GLD: 120.54 (-0.19), RLGY: 34.27 (+0.38), CIT: 33.17 (+1.11), HMHC: 19.96 (+0.19), MTG: 7.55 (-0.02), CSRA: 25.82 (-0.30)
Endo Pharmaceuticals Falls 1.51% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Feb 19, 5:11PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $49.43 to a high of $51.32. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $50.26 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 42.44 (-0.73)
Can ARIAD (ARIA) Surprise Estimates This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 1:05PM CST
ARIAD Pharmaceuticals (ARIA), which is set to report fourth-quarter 2015 results on Feb 23, had posted a negative earnings surprise of 45% last quarter.
ENDP: 42.44 (-0.73), ADRO: 16.69 (-0.16), ARIA: 6.29 (+0.22), MCRB: 27.79 (+0.93)
Endo (ENDP) Initiates Phase IIb Study on Xiaflex for Cellulite
Zacks Equity Research - Zacks Investment Research - Thu Feb 18, 3:20PM CST
Endo (ENDP) initiated a phase IIb study on Xiaflex for the treatment of patients with cellulite.
ENDP: 42.44 (-0.73), HZNP: 16.78 (-0.51), ANIK: 45.07 (-0.43), CELG: 102.51 (-0.22)
Global Cardiovascular Partnering Deal Trends, Players and Financials 2010-2016
M2 - Thu Feb 04, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/3fs25k/global) has announced the addition of the "Global Cardiovascular Partnering 2010-2016: Deal trends, players and financials" company profile to their offering. Global Cardiovascular Partnering 2010 to 2016 provides the full collection of Cardiovascular disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the comprehensive Cardiovascular disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Cardiovascular deals. The report presents financial deal terms values for Cardiovascular deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. The initial chapters of this report provide an orientation of Cardiovascular dealmaking trends. Chapter 1 provides an introduction to the report. Chapter 2 provides an overview of the trends in Cardiovascular dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication. Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates. Chapter 4 provides a review of the leading Cardiovascular deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Cardiovascular dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 5 provides comprehensive access to Cardiovascular deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive directory of all Cardiovascular partnering deals by specific Cardiovascular target announced since 2010. The chapter is organized by specific Cardiovascular therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided with each report of all Cardiovascular partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 2016 Companies Mentioned - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Shionogi - Shire - Takeda - Teva - Valeant For more information visit http://www.researchandmarkets.com/research/3fs25k/global
AGN: 288.67 (-0.95), JNJ: 106.50 (-0.15), ENDP: 42.44 (-0.73), BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62), BAX: 39.46 (+0.13), MRK: 52.08 (-0.02), AMGN: 145.98 (+0.14), LLY: 73.60 (+0.35), GSK: 39.14 (-0.04), BMY: 64.71 (-0.29), CELGZ: 1.30 (-0.04)
Look for Shares of Endo Pharmaceuticals to Potentially Rebound after Yesterday's 2.33% Sell Off
Comtex SmarTrend(R) - Wed Feb 03, 5:05PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $52.59 to a high of $56.59. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $53.34 on volume of 3.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 42.44 (-0.73)
Endo Announces the Qualitest Scholarship Program
PR Newswire - Mon Feb 01, 7:30AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that it has funded the creation of a new scholarship program designed to make higher education more accessible for the next generation of Huntsville, Alabama leaders. The newly created Qualitest Scholarship Program is a $50,000 education initiative that reflects Endo's dedication to the legacy of Qualitest, which was recently renamed Par Pharmaceutical as a result of Endo's acquisition of Par Pharmaceutical Holdings, Inc., and to the employees and residents living in the Huntsville, Alabama region.
ENDP: 42.44 (-0.73), ENL.TO: 56.00 (-1.80)
The New #37 Most Shorted Nasdaq 100 Component: Endo International
MarketNewsVideo.com - Fri Jan 29, 2:37PM CST
The most recent short interest data has been released by the NASDAQ for the 01/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." ...
ENDP: 42.44 (-0.73)
Look for Shares of Endo Pharmaceuticals to Potentially Pullback after Yesterday's 3.84% Rise
Comtex SmarTrend(R) - Tue Jan 26, 4:42PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $56.46 to a high of $61.14. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $58.98 on volume of 7.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ENDP: 42.44 (-0.73)
New Speakers Confirmed at SMi's 2nd Annual Lyophilization USA Conference from Allergan, Genentech, Endo Pharmaceuticals and Parexel
PRWeb - Tue Jan 26, 6:02AM CST
Due to four new speakers being added onto the agenda, SMi Group are delighted to announce that a new brochure has been released for the 2nd annual Lyophilization USA conference taking place on April 27th and 28th in Iselin, New Jersey. Those who have recently confirmed to present include Allergan, Genentech, Endo Pharmaceuticals and Parexel.
AGN: 288.67 (-0.95), ENDP: 42.44 (-0.73)
BioDelivery Sciences to Host Analyst and Investor Day on February 25th in New York City
PR Newswire - Mon Jan 25, 9:00AM CST
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will host an Analyst and Investor Day on Thursday, February 25th from 12:00 PM - 2:30 PM Eastern Time in New York City. The event will focus on both of BDSI's approved products, BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII), and BELBUCA(TM) (buprenorphine HCl) buccal film (CIII), which is licensed worldwide to Endo Pharmaceuticals. The event will also include an update on the development portfolio, which includes Clonidine Topical Gel for painful diabetic neuropathy and Buprenorphine Depot Injection for both opioid dependence and chronic pain. Both commercial and clinical updates will be provided.
BDSI: 4.09 (+0.12), ENDP: 42.44 (-0.73)
After Yesterday's Rally of 2.34% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jan 21, 4:26PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $53.93 to a high of $57.35. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $56.18 on volume of 3.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ENDP: 42.44 (-0.73)
Endo Int'l (ENDP) Stock Coverage Initiated at Barclays
at The Street - Thu Jan 21, 3:27PM CST
Endo Int'l (ENDP) stock closed Thursday's trading session up after Barclays analysts initiated coverage of the stock.
ENDP: 42.44 (-0.73)
Deutsche Bank Recommends These 8 Health Care Stocks on Market Volatility
at The Street - Sat Jan 16, 11:15AM CST
Investors should stick with sectors that were leaders in 2015 such as health care and technology, according to Deutsche Bank. Here are eight health care stocks to consider.
AGN: 288.67 (-0.95), ENDP: 42.44 (-0.73), ABT: 39.18 (+0.36), PRGO: 126.61 (+0.19), MDT: 75.61 (+0.69), TMO: 140.30 (+1.63), MYL: 44.78 (-0.95), SYK: 103.45 (+0.55)
New Strong Buy Stocks for January 15th
Zacks Equity Research - Zacks Investment Research - Fri Jan 15, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
ENDP: 42.44 (-0.73), TREE: 90.40 (+0.51), ACLS: 2.68 (-0.05), RACE: 39.74 (+0.34), NVDA: 32.55 (-0.10)
The Zacks Analyst Blog Highlights: Harman International Industries, QUALCOMM, United Continental Holdings, Endo International and Discover Financial Services
Zacks Equity Research - Zacks Investment Research - Wed Jan 13, 8:30AM CST
The Zacks Analyst Blog Highlights: Harman International Industries, QUALCOMM, United Continental Holdings, Endo International and Discover Financial Services
DFS: 48.53 (-0.23), ENDP: 42.44 (-0.73), HAR: 80.79 (-0.22), QCOM: 52.66 (+0.28), UAL: 58.00 (-0.34)
Dow 30 Stock Roundup: Boeing Wins $276.3M Navy Contract, Cisco to Buy Cloud Startup for $260M
Swarup Gupta - Zacks Investment Research - Fri Mar 04, 2:52PM CST
The Dow continued to gain this week on the back of rising oil prices.
MMM: 160.07 (+0.69), ENDP: 42.44 (-0.73), GE: 30.46 (+0.24), XOM: 82.29 (-0.11), BA: 121.07 (+1.46), JNJ: 106.50 (-0.15), V: 73.90 (-0.01), ADP: 86.19 (+0.54), GS: 156.84 (+1.51), JPM: 60.05 (+0.09), PG: 83.49 (+0.65), CVX: 87.93 (+0.40), MSFT: 52.03 (-0.32), VZ: 51.81 (-0.08), AAPL: 103.01 (+1.51), CSCO: 26.80 (-0.07), BHI: 46.20 (-0.35)
Endo Int’l (ENDP) Stock Price Target Cut at Barclays
at The Street - Fri Mar 04, 8:51AM CST
Barclays lowered its price target on Endo Int’l (ENDP) stock and maintained its ‘equal weight’ rating on Friday morning.
ENDP: 42.44 (-0.73)
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2015 Update
John Vincent - at Seeking Alpha - Sun Feb 21, 6:17AM CST
SIRO: 109.97 (-0.13), MON: 85.89 (+0.95), EVHC: 23.25 (-0.30), PRU: 71.47 (-0.40), NKE: 61.26 (-0.21), KSU: 86.65 (+0.23), AMP: 90.46 (+0.92), LM: 32.42 (+0.57), RRC: 32.32 (+1.59), AET: 108.06 (-1.58), GOOG: 710.89 (-1.53), GPOR: 25.60 (+0.33), HOT: 70.55 (+0.48), HLT: 21.89 (+0.30), LYB: 82.00 (+2.10), COG: 21.47 (-0.70), WCG: 93.24 (-0.36), MA: 90.05 (+0.31), MNK: 62.15 (-1.44), WUBA: 55.70 (+1.45), WLL: 7.09 (+0.78), VRTX: 88.36 (-1.09), MCK: 162.77 (+0.07), ETN: 57.95 (+0.12), SEE: 45.68 (-0.84), AKRX: 25.08 (-0.80), PFE: 29.71 (-0.18), HAL: 34.88 (+0.71), LNG: 38.04 (+0.99), ETE: 8.33 (+0.43), TXT: 33.00 (-0.64), ALL: 65.38 (+0.07), PCLN: 1,297.71 (-5.33), QUNR: 36.95 (+0.73), WBA: 79.45 (-0.47), PXD: 128.80 (+0.53), MCD: 117.18 (+0.49), TEVA: 55.62 (+0.02), DOV: 63.20 (+0.75), AIG: 52.30 (+0.03), XRAY: 60.16 (-0.46), FDC: 13.59 (+0.80), CCI: 87.25 (-0.64), BIIB: 263.94 (-4.70), VRX: 61.31 (-3.58), CPN: 14.14 (+0.26), C: 42.83 (unch), ILMN: 156.14 (-1.31), CB: 117.18 (-0.66), MMC: 58.01 (+0.26), HUM: 183.25 (+0.03), AGN: 288.67 (-0.95), ANTM: 132.35 (-0.62), ECA: 5.47 (+0.54), PRQR: 4.54 (+0.14), EBAY: 24.41 (+0.47), SHPG: 160.39 (+0.20), CMG: 529.00 (+4.71), GOOGL: 730.22 (-1.37), CTRP: 40.02 (+0.78), SWN: 7.83 (+0.49), BK: 38.09 (+0.40), APD: 134.79 (-0.09), BHI: 46.20 (-0.35), APC: 45.26 (+2.28), AMZN: 575.14 (-2.35), ENDP: 42.44 (-0.73), MAR: 68.98 (+0.30), NFLX: 101.58 (+3.65), DVA: 70.51 (+0.43), KITE: 54.44 (+2.70), MHK: 186.82 (-0.07), TDG: 222.68 (+3.05), LH: 112.17 (+0.25), CP: 125.26 (+3.28), AFL: 61.03 (+0.05), AVGO: 146.06 (+8.73), BABA: 72.22 (+1.20)
Tracking John Paulson's Paulson & Company Portfolio - Q4 2015 Update
John Vincent - at Seeking Alpha - Sat Feb 20, 1:39PM CST
SGYP: 3.47 (-0.01), PRGO: 126.61 (+0.19), CAM: 67.79 (-0.03), CHTR: 184.78 (+1.11), INTC: 30.63 (+0.05), PCP: 234.95 (+0.10), SLB: 74.83 (-0.02), CYBX: 69.95 (+0.86), HOT: 70.55 (+0.48), STAY: 14.82 (-0.27), CSC: 30.51 (-0.26), TMUS: 38.48 (-0.49), MNK: 62.15 (-1.44), WLL: 7.09 (+0.78), AKRX: 25.08 (-0.80), NCQ: 0.46 (+0.05), AU: 12.92 (-0.36), MYL: 44.78 (-0.95), MGM: 19.81 (-0.52), WWAV: 41.15 (+0.60), NG: 5.02 (-0.01), LIVN: 57.94 (+0.19), TEVA: 55.62 (+0.02), AIG: 52.30 (+0.03), BRK.B: 137.97 (+1.13), BRK.A: 207,945.00 (+1,945.00), OAS: 6.91 (+0.22), VRX: 61.31 (-3.58), VNDA: 7.92 (-0.21), ALTR: 53.96 (+0.03), CZR: 8.80 (-0.15), CVC: 33.28 (+0.03), CIE: 3.41 (+0.21), AGN: 288.67 (-0.95), CACQ: 5.75 (-0.15), SHPG: 160.39 (+0.20), TWC: 195.33 (+0.90), BXLT: 39.47 (+0.17), ENDP: 42.44 (-0.73), OUT: 21.56 (+0.06), BAC: 13.54 (+0.04), MAR: 68.98 (+0.30), GRFS: 15.22 (-0.27), HCA: 73.00 (+0.07), POST: 71.75 (-0.45), RDN: 11.94 (+0.16), LRCX: 74.33 (-0.54), BAX: 39.46 (+0.13), GLD: 120.54 (-0.19), RLGY: 34.27 (+0.38), CIT: 33.17 (+1.11), HMHC: 19.96 (+0.19), MTG: 7.55 (-0.02), CSRA: 25.82 (-0.30)
Endo Pharmaceuticals Falls 1.51% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Feb 19, 5:11PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $49.43 to a high of $51.32. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $50.26 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 42.44 (-0.73)
Can ARIAD (ARIA) Surprise Estimates This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 1:05PM CST
ARIAD Pharmaceuticals (ARIA), which is set to report fourth-quarter 2015 results on Feb 23, had posted a negative earnings surprise of 45% last quarter.
ENDP: 42.44 (-0.73), ADRO: 16.69 (-0.16), ARIA: 6.29 (+0.22), MCRB: 27.79 (+0.93)
Endo (ENDP) Initiates Phase IIb Study on Xiaflex for Cellulite
Zacks Equity Research - Zacks Investment Research - Thu Feb 18, 3:20PM CST
Endo (ENDP) initiated a phase IIb study on Xiaflex for the treatment of patients with cellulite.
ENDP: 42.44 (-0.73), HZNP: 16.78 (-0.51), ANIK: 45.07 (-0.43), CELG: 102.51 (-0.22)
Global Cardiovascular Partnering Deal Trends, Players and Financials 2010-2016
M2 - Thu Feb 04, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/3fs25k/global) has announced the addition of the "Global Cardiovascular Partnering 2010-2016: Deal trends, players and financials" company profile to their offering. Global Cardiovascular Partnering 2010 to 2016 provides the full collection of Cardiovascular disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the comprehensive Cardiovascular disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Cardiovascular deals. The report presents financial deal terms values for Cardiovascular deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. The initial chapters of this report provide an orientation of Cardiovascular dealmaking trends. Chapter 1 provides an introduction to the report. Chapter 2 provides an overview of the trends in Cardiovascular dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication. Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates. Chapter 4 provides a review of the leading Cardiovascular deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Cardiovascular dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 5 provides comprehensive access to Cardiovascular deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive directory of all Cardiovascular partnering deals by specific Cardiovascular target announced since 2010. The chapter is organized by specific Cardiovascular therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided with each report of all Cardiovascular partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 2016 Companies Mentioned - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Shionogi - Shire - Takeda - Teva - Valeant For more information visit http://www.researchandmarkets.com/research/3fs25k/global
AGN: 288.67 (-0.95), JNJ: 106.50 (-0.15), ENDP: 42.44 (-0.73), BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62), BAX: 39.46 (+0.13), MRK: 52.08 (-0.02), AMGN: 145.98 (+0.14), LLY: 73.60 (+0.35), GSK: 39.14 (-0.04), BMY: 64.71 (-0.29), CELGZ: 1.30 (-0.04)
Look for Shares of Endo Pharmaceuticals to Potentially Rebound after Yesterday's 2.33% Sell Off
Comtex SmarTrend(R) - Wed Feb 03, 5:05PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $52.59 to a high of $56.59. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $53.34 on volume of 3.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 42.44 (-0.73)
Endo Announces the Qualitest Scholarship Program
PR Newswire - Mon Feb 01, 7:30AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that it has funded the creation of a new scholarship program designed to make higher education more accessible for the next generation of Huntsville, Alabama leaders. The newly created Qualitest Scholarship Program is a $50,000 education initiative that reflects Endo's dedication to the legacy of Qualitest, which was recently renamed Par Pharmaceutical as a result of Endo's acquisition of Par Pharmaceutical Holdings, Inc., and to the employees and residents living in the Huntsville, Alabama region.
ENDP: 42.44 (-0.73), ENL.TO: 56.00 (-1.80)
The New #37 Most Shorted Nasdaq 100 Component: Endo International
MarketNewsVideo.com - Fri Jan 29, 2:37PM CST
The most recent short interest data has been released by the NASDAQ for the 01/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." ...
ENDP: 42.44 (-0.73)
Look for Shares of Endo Pharmaceuticals to Potentially Pullback after Yesterday's 3.84% Rise
Comtex SmarTrend(R) - Tue Jan 26, 4:42PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $56.46 to a high of $61.14. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $58.98 on volume of 7.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ENDP: 42.44 (-0.73)
New Speakers Confirmed at SMi's 2nd Annual Lyophilization USA Conference from Allergan, Genentech, Endo Pharmaceuticals and Parexel
PRWeb - Tue Jan 26, 6:02AM CST
Due to four new speakers being added onto the agenda, SMi Group are delighted to announce that a new brochure has been released for the 2nd annual Lyophilization USA conference taking place on April 27th and 28th in Iselin, New Jersey. Those who have recently confirmed to present include Allergan, Genentech, Endo Pharmaceuticals and Parexel.
AGN: 288.67 (-0.95), ENDP: 42.44 (-0.73)
BioDelivery Sciences to Host Analyst and Investor Day on February 25th in New York City
PR Newswire - Mon Jan 25, 9:00AM CST
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will host an Analyst and Investor Day on Thursday, February 25th from 12:00 PM - 2:30 PM Eastern Time in New York City. The event will focus on both of BDSI's approved products, BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII), and BELBUCA(TM) (buprenorphine HCl) buccal film (CIII), which is licensed worldwide to Endo Pharmaceuticals. The event will also include an update on the development portfolio, which includes Clonidine Topical Gel for painful diabetic neuropathy and Buprenorphine Depot Injection for both opioid dependence and chronic pain. Both commercial and clinical updates will be provided.
BDSI: 4.09 (+0.12), ENDP: 42.44 (-0.73)
After Yesterday's Rally of 2.34% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jan 21, 4:26PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $53.93 to a high of $57.35. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $56.18 on volume of 3.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ENDP: 42.44 (-0.73)
Endo Int'l (ENDP) Stock Coverage Initiated at Barclays
at The Street - Thu Jan 21, 3:27PM CST
Endo Int'l (ENDP) stock closed Thursday's trading session up after Barclays analysts initiated coverage of the stock.
ENDP: 42.44 (-0.73)
Deutsche Bank Recommends These 8 Health Care Stocks on Market Volatility
at The Street - Sat Jan 16, 11:15AM CST
Investors should stick with sectors that were leaders in 2015 such as health care and technology, according to Deutsche Bank. Here are eight health care stocks to consider.
AGN: 288.67 (-0.95), ENDP: 42.44 (-0.73), ABT: 39.18 (+0.36), PRGO: 126.61 (+0.19), MDT: 75.61 (+0.69), TMO: 140.30 (+1.63), MYL: 44.78 (-0.95), SYK: 103.45 (+0.55)
New Strong Buy Stocks for January 15th
Zacks Equity Research - Zacks Investment Research - Fri Jan 15, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
ENDP: 42.44 (-0.73), TREE: 90.40 (+0.51), ACLS: 2.68 (-0.05), RACE: 39.74 (+0.34), NVDA: 32.55 (-0.10)
The Zacks Analyst Blog Highlights: Harman International Industries, QUALCOMM, United Continental Holdings, Endo International and Discover Financial Services
Zacks Equity Research - Zacks Investment Research - Wed Jan 13, 8:30AM CST
The Zacks Analyst Blog Highlights: Harman International Industries, QUALCOMM, United Continental Holdings, Endo International and Discover Financial Services
DFS: 48.53 (-0.23), ENDP: 42.44 (-0.73), HAR: 80.79 (-0.22), QCOM: 52.66 (+0.28), UAL: 58.00 (-0.34)
